Percutaneous absorption of 5α‐dihydrotestosterone in man

Publisher Website
Google Scholar
Abstract
The particularities of percutaneous absorption of a natural androgen, 5.alpha.-dihydrotestosterone, were evaluated in substitutive androgen therapy in masculine hypogonadism. Nine men presenting idiopathic hemochromatosis complicated by severe hypogonadism were treated with percutaneous administration of 5.alpha.-dihydrotestosterone (125 mg/day) for 5 mo. Plasma levels of 5.alpha.-dihydrotestosterone and 5.alpha.-androstane-3.alpha.,17.beta.-diol are greatly increased by treatment (from 0.86 to 18.39 nmol/l and 0.16 to 3.40 nmol/l, respectively). There is no modification of testosterone and estradiol-17.beta.. Double blind study demonstrated the direct stimulating effect of 5.alpha.-dihydrotesterone on sexual behavior and psychism. Hepatic and metabolic tolerance was excellent in these patients, depsite the preceding deleterious effects of the Fe excess. The percutaneous route is original, practical and improves the androgen therapy of hypogonadism in men.